Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
Stopped Terminated due to lack of efficacy
Conditions
- B Acute Lymphoblastic Leukemia
- Minimal Residual Disease
- Recurrent Acute Lymphoblastic Leukemia
- T Acute Lymphoblastic Leukemia
Interventions
- OTHER: Laboratory Biomarker Analysis
- BIOLOGICAL: Pembrolizumab
Sponsor
University of Washington
Collaborators